Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Blood (2023) 141 (10): 1159–1168.

https://doi.org/10.1182/blood.2022016862

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of the Usefulness of Satl-PI and JCOG-PI As Predictors of Prognosis at the Start of Second-Line Treatment

Daisuke Nakamura, Tomohisa Tabuchi, Naosuke Arima, Maiko Hayashida, Akihiko Arai, Makoto Yoshimitsu, Kenji Ishitsuka

Blood (2022) 140 (Supplement 1): 3792–3793.

https://doi.org/10.1182/blood-2022-159818

Published: 2022

Journal Articles

Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions

Bryan Valcarcel, Haruhiko Sano, Hiroo Katsuya, Atae Utsunomiya, Maki Otsuka, Masaharu Miyahara, Yasushi Takamatsu, Kenji Ishitsuka, Shinya Kimura, Junji Suzumiya, Kazuo Tamura, Daniel J Enriquez, Denisse Castro, Brady E Beltran, Henry Idrobo, Camila Peña, Lorena Fiad, Juan Carlos Ramos, Luis Enrique Malpica Castillo

Blood (2022) 140 (Supplement 1): 1072–1073.

https://doi.org/10.1182/blood-2022-168334

Published: 2022

Journal Articles

Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis

Blood (2022) 140 (Supplement 1): 6664–6665.

https://doi.org/10.1182/blood-2022-168101

Published: 2022

Journal Articles

Whole-genome landscape of adult T-cell leukemia/lymphoma

Blood (2022) 139 (7): 967–982.

https://doi.org/10.1182/blood.2021013568

Published: 2022

Includes: Supplemental data

Journal Articles

A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01

Francine M. Foss, Pierluigi Porcu, Steven M. Horwitz, Koji Izutsu, Kenji Ishitsuka, Kazunobu Kato, Jin Jin, Yining Du, Ai Inoue

Blood (2021) 138 (Supplement 1): 2533.

https://doi.org/10.1182/blood-2021-144676

Published: 2021

Journal Articles

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2021-149425

Published: 2021

Journal Articles

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Blood (2021) 138 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2021-149801

Published: 2021

Journal Articles

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2021-148492

Published: 2021

Journal Articles

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2021-149960

Published: 2021

Journal Articles

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2021-146796

Published: 2021

Journal Articles

Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma

Blood (2021) 138 (Supplement 1): 303.

https://doi.org/10.1182/blood-2021-146657

Published: 2021

Journal Articles

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

SungGi Chi, MD PhD, Naoko Hosono, MD PhD, Takahiro Yamauchi, MD PhD, Kentaro Fukushima, MD, Hirohiko Shibayama, MD PhD, Seiichiro Katagiri, MDPhD, Akihiko Gotoh, MD PhD, Motohito Okabe, MD, Takanobu Morishita, MD, PhD, Masamitsu Yanada, MD PhD, Kazuhito Yamamoto, MD PhD, Naohito Fujishima, MD PhD, Naoto Takahashi, MD PhD, Reiki Ogasawara, MDPhD, Takeshi Kondo, MD PhD, Yoshikazu Utsu, MD PhD, Nobuyuki Aotsuka, MD, Yoshimasa Kamoda, MD, Kensuke Usuki, MD PhD, Kanenari Takemura, MD, Yasuyuki Nagata, MD PhD, Takaaki Ono, MD PhD, Tsutomu Kobayashi, MD PhD, Junya Kuroda, MD PhD, Hiroto Horiguchi, MDPhD, Satoshi Iyama, MD PhD, Suguru Fukuhara, MD PhD, Koji Izutsu, MD PhD, Makoto Nakamura, MD PhD, Kazuto Togitani, MD, Kensuke Kojima, MD PhD, Kaoru Yamamoto, MD, Yukinori Nakamura, MD, Makoto Yoshimitsu, MD PhD, Kenji Ishitsuka, MD PhD, Kenichi Miyamoto, MD, Yosuke Minami, MDPhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139240

Published: 2020

Journal Articles

Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-134360

Published: 2020

Journal Articles

A Novel Recurrent Gain-of-Function Mutation of Rltpr Q575E in Adult T Cell Leukemia/Lymphoma

Yuichiro Uchida, Makoto Yoshimitsu, MD PhD, Yuhei Kamada, MD PhD, Naosuke Arima, MD, Kenji Ishitsuka, MD PhD

Blood (2019) 134 (Supplement_1): 1489.

https://doi.org/10.1182/blood-2019-124641

Published: 2019

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

Prediction for the Risk of Gvhd after Allogeneic HSCT in Patients with ATL Treated By Mogamulizumab

Yuhei Kamada, MD PhD, Ayako Kuroki, PhD, Naosuke Arima, MD, Maiko Hayashida, MD, Daisuke Nakamura, MD PhD, Makoto Yoshimitsu, MD PhD, Kenji Ishitsuka, MD PhD

Blood (2019) 134 (Supplement_1): 3290.

https://doi.org/10.1182/blood-2019-126912

Published: 2019

Journal Articles

Possibility of a Risk-Adapted Treatment Strategy for Untreated Aggressive Adult T-Cell Leukemia-Lymphoma (ATL) Based on the ATL Prognostic Index: A Supplementary Analysis of the JCOG9801 Study

Kosuke Toyoda, MD, Kunihiro Tsukasaki, MD PhD, Ryunosuke Machida, Tomohiro Kadota, MD PhD, Takuya Fukushima, MD PhD, Kenji Ishitsuka, MD PhD, Dai Maruyama, MD PhD, Hirokazu Nagai, MD PhD

Blood (2018) 132 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2018-99-112734

Published: 2018

Journal Articles

DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation

Blood (2018) 132 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2018-99-113379

Published: 2018

Journal Articles

Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma

Blood (2018) 131 (2): 215–225.

https://doi.org/10.1182/blood-2017-01-761874

Published: 2018

Includes: Supplemental data

NARROW

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Validation of the Usefulness of Satl-PI and JCOG-PI As Predictors of Prognosis at the Start of Second-Line Treatment

Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions

Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis

Whole-genome landscape of adult T-cell leukemia/lymphoma

A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma

A Novel Recurrent Gain-of-Function Mutation of Rltpr Q575E in Adult T Cell Leukemia/Lymphoma

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Prediction for the Risk of Gvhd after Allogeneic HSCT in Patients with ATL Treated By Mogamulizumab

Possibility of a Risk-Adapted Treatment Strategy for Untreated Aggressive Adult T-Cell Leukemia-Lymphoma (ATL) Based on the ATL Prognostic Index: A Supplementary Analysis of the JCOG9801 Study

DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation

Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only